Alphamab Oncology (HKSE:09966) 3-Year Book Growth Rate : -13.00% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Alphamab Oncology 3-Year Book Growth Rate?

Alphamab Oncology's Book Value per Share for the quarter that ended in Dec. 2023 was HK$1.90.

During the past 12 months, Alphamab Oncology's average Book Value per Share Growth Rate was 2.40% per year. During the past 3 years, the average Book Value per Share Growth Rate was -13.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 7 years, the highest 3-Year average Book Value per Share Growth Rate of Alphamab Oncology was 443.00% per year. The lowest was -15.00% per year. And the median was -13.00% per year.

Competitive Comparison of Alphamab Oncology's 3-Year Book Growth Rate

For the Biotechnology subindustry, Alphamab Oncology's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alphamab Oncology's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alphamab Oncology's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Alphamab Oncology's 3-Year Book Growth Rate falls into.

Alphamab Oncology 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Alphamab Oncology (HKSE:09966) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Alphamab Oncology 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Alphamab Oncology's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Alphamab Oncology (HKSE:09966) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alphamab Oncology (HKSE:09966) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

3NK:Germany

Address

No. 175 Fangzhou Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215024

Website

https://www.alphamabonc.com

Alphamab Oncology is a clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecifics and protein engineering. The company through its subsidiaries is engaged in discovery, development manufacturing and commercialization of biotherapeutics for cancer treatment.

Executives

South Dakota Trust Company Llc	2301 Trustee
Xu Ting	2305 Beneficiary of a trust
Liu Yang	2307 Founder of a discretionary trust who can infl
Rubymab Ltd.	2101 Beneficial owner
Pang Kee Chan Hebert
Highbury Investment Pte Ltd	2201 Interest of corporation controlled by you
Gic Special Investments Private Limited	2102 Investment manager
Gic Private Limited	2201 Interest of corporation controlled by you
Gic (ventures) Pte. Ltd.	2201 Interest of corporation controlled by you
Advantech Capital Ii Investment Partners Limited
Advantech Capital Ii Alphamab Partnership L.p.
Advantech Capital Partners Ii Limited
Advantech Capital Investment I Limited
Advantech Capital Ii Master Investment Limited
Advantech Capital Ii L.p.

Alphamab Oncology (HKSE:09966) Headlines

No Headlines